Targeting unique disease-specific peptide HLA complexes is an essential input for filling immunotherapeutic drug discovery pipelines. Pure MHC’s business development plan makes it easy to partner with mutually favorable terms and creative flexibility to meet your specific corporate needs.
With Pure MHC’s available suite of research tools, an expansive range of services are available to assist collaborators in answering research and development questions related to epitope validation, development, and therapeutic exploitation of their existing targets.
Pure MHC is currently seeking partnerships to:
Develop therapeutics to novel peptide targets in multiple internal discovery projects. Current target discovery projects in oncology include:
Current target discovery projects in autoimmunity include:
Collaborate on novel target discovery programs for other oncology indications, infectious diseases, and autoimmune disorders with partners active in specific indications in those fields
Apply its extensive HLA expertise and proprietary tools to:
Collaborate with Pure MHC to achieve your corporate and scientific goals.